Search PubMed⌕ Search

Biomedical subjects

J Finke

Publications and source records attributed to J Finke.

At least 145 records · Page 8Linked to original sources
PubMed1988

Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.

Expression of the Epstein-Barr virus (EBV) encoded nuclear antigens (EBNA 1 to 6) and membrane-associated protein (LMP) was investigated by immunoblotting in 83 nasopharyngeal carcinoma (NPC) biopsies and 25 other tumor and normal tissue specimens from the head and neck region. Fifty-eight of the 83 NPC biopsies were large enough to yield parallel data on virus DNA and viral expression. All 16 cases of clinically diagnosed and histologically confirmed NPCs from North Africa contained EBV DNA and expressed EBNA-1. Of 31 clinically diagnosed NPCs from China, 29 contained EBV DNA and 25 of these expressed EBNA-1. One control tissue biopsy from the oropharynx of NPC patients contained EBV DNA, but none expressed EBNA-1. The latent membrane protein (LMP) was detected in 22/31 of the Chinese and in 10/16 of the North African NPC biopsies. None of the NPC biopsies or control tissues expressed detectable amounts of EBNA 2 or any of the other 4 nuclear antigens which are invariably expressed in EBV-transformed B cells. A smaller number of tumors from Malaysia and East Africa exhibited a similar pattern of expression. EBV was rescued from a nude-mouse-passaged North African NPC tumor by co-cultivation of the tumor cells with umbilical cord blood lymphocytes. The tumor expressed EBNA 1 and LMP, but not EBNA 2 or the other 4 EBNAs. The resulting LCLs expressed all 6 nuclear antigens, EBNA 1 to 6 and LMP. Our data suggest that expression of the EBV genome is regulated in a tissue-specific fashion.

Animals↗
PubMed1988

Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus.

A total of 116 sera from healthy individuals and from patients with Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC) or rheumatoid arthritis (RA) were studied with respect to antibody responses to each of the seven known transformation-associated Epstein-Barr virus (EBV)-encoded antigens [latent membrane protein (LMP) and six nuclear proteins (EBNAs 1 to 6)]. The antibodies were detected using modified standard immunoblotting techniques. Antibodies to LMP were detected for the first time in sera from 6/27 (22%) healthy, EBV-immune individuals (seropositive for the viral capsid antigens). An increased incidence of anti-LMP antibodies was found in EBV-immune sera from patients with BL (17/24 positive; 71%), NPC (21/33; 64%), and RA (16/21; 76%). Antibodies to EBNA 1 were detected in all EBV-immune sera at a standard 1:20 dilution. Antibodies to the other EBNAs were detected in only a proportion of these sera (20 to 95%) at the same dilution. Only minor disease-associated differences in the incidence of these antibodies were observed, the most consistent being that RA sera had a higher incidence of antibodies to EBNAs 2 to 6 compared with healthy controls. Testing of the sera at a 1:100 dilution suggested that there were some disease-related differences in the titres of anti-EBNA antibodies. At this serum dilution, a reduced incidence of antibodies to EBNA 2 was seen in NPC (6/31) compared with RA (18/19) and healthy EBV-seropositives (16/26); antibodies to EBNA 3 were detected at an increased incidence in BL (8/15) and NPC (16/31) compared with control sera (7/26); antibodies to EBNA 4 were detected at increased incidence in BL (5/15) and RA (6/19) compared with control sera (1/26); and antibodies to EBNA 6 were detected at increased incidence in NPC (19/31) and RA (7/19) compared with control sera (3/26).

AIDS-Related Complex↗
PubMed1987

The alloantibody response in the allogeneically pregnant rat. V. Absence of cell-mediated immunity in high responders.

Allogeneically pregnant rats have been examined postpartum to determine whether they are sensitized against paternal class I antigens for cell-mediated immunity. This study was undertaken as this point is ambiguous. Since the response of the female to paternal MHC antigens is genetically controlled it is possible that the inability of some investigations to detect cell-mediated immunity against the paternal strain was due to the use of non-responder strain combinations. Cell-mediated immunity was assayed in a strain combination that is an unambiguous high responder, in which 100% of the females respond to the paternal strain by making alloantibodies. Maternal cell-mediated responses to paternal antigens were measured by the assays of DTH and IL-2 secretion under limiting conditions. We were unable to detect any cell-mediated immunity to paternal class I antigens even though the female produced copious quantities of alloantibody.

Animals↗
PubMed1987

Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

The Epstein-Barr virus nuclear antigen 5 (EBNA-5) is encoded by highly spliced mRNA from the major IR1 (BamHI-W) repeat region of the virus genome. A mouse monoclonal antibody, JF186, has been raised against a synthetic 18-amino-acid peptide deduced from the EBNA-5 message of B95-8 and Raji cells. The antibody showed characteristic coarse nuclear granules by indirect immunofluorescence and revealed multiple EBNA-5 species by immunoblotting and immunoprecipitation. The B95-8 line itself and all B95-8 virus-carrying cells, whether lymphoblastoid cell lines or in vitro-converted sublines of Epstein-Barr virus (EBV)-negative Burkitt's lymphoma (BL) lines, were EBNA-5 positive. Among 36 cell lines carrying different EBV strains, only 10 expressed the B95-8-Raji-prototype EBNA-5 recognized by JF186; this was probably due to genetic variation in the epitope recognized by JF186, as shown for P3HR-1. Human antibodies, affinity purified against EBNA-5-JF186 immunoprecipitates, detected EBNA-5 in the majority of EBV-positive BL lines and in all lymphoblastoid cell lines containing the BL-derived viruses. Thus, EBNA-5 can be expressed by all virus isolates examined, but is down-regulated, together with other latent gene products, in a minority of BL lines which have a particular cellular phenotype. EBNA-5 was detected as a ladder of protein species of 20 to 130 kilodaltons (kDa), with a regular spacing of 6 to 8 kDa, consistent with the coding capacity of the combined BamHI-W 66- and 132-base-pair exons, together with shifts of 2 to 4 kDa, consistent with the size of the separate 66- and 132-base-pair exons. Multiple EBNA-5 proteins can be expressed by the single cell as shown by cloning of newly infected cells.

Animals↗
PubMed1982

[Indication and interaction of psycho- and sociotherapy in the rehabilitation of schizophrenics--an experience report].

The report is about a model of psychotherapeutic and sociotherapeutic treatment of schizophrenic patients. Questions concerning the indication of different psychotherapeutic and sociotherapeutic interventions related to different schizophrenic states are discussed as well as problems of the integration of these interventions. Besides, aspects of the combined treatment of neurotics and psychotic patients are outlined.

Halfway Houses↗
PubMed1980

The glucagonoma syndrome. Report of a case.

A 73-year-old man had diabetes mellitus, diarrhea, weight loss, and a rash of several years' duration. The rash, termed necrolytic migratory erythema, was the most characteristic feature and eventually suggested the diagnosis of a glucagon-secreting tumor of the pancreas. Diabetic ketoacidosis also developed in our patient, a previously unrecognized occurrence with this syndrome.

Adenoma, Islet Cell↗
PubMed1975

[Fludrocortisone in the treatment of orthostatic hypotension: ophthalmodynamography during standing(author's transl)].

The effect of fludrocortisone (Astonin -H) in the management of orthostatic hypotension was tested in a double-blind trial of 30 patients who were receiving 0.3 mg fludrocortisone for seven days, a control group of 30 subjects receiving placebos. Systolic and diastolic brachial and ophthalmic arterial pressures, pulse amplitude and pulse rate were measured at rest, immediately after standing up and 10 minutes later. Comparing the treatment and placebo groups, the former had a higher systolic ophthalmic blood pressure on standing, a smaller fall of pulse volume and less of a rise in heart rate on standing up, and a raised systolic brachial artery pressure even in recumbency. At the same time there was an improvement in symptoms.

Adult↗